Company

Infant Bacterial Therapeutics AB

Headquarters: Stockholm, Sweden

Employees: 8

OMX: IBT.B

Market Cap

kr1.32 Billion

SEK as of July 1, 2024

US$124.4 Million

Market Cap History

Infant Bacterial Therapeutics AB market capitalization over time

Evolution of Infant Bacterial Therapeutics AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Infant Bacterial Therapeutics AB

Detailed Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Infant Bacterial Therapeutics AB has the following listings and related stock indices.


Stock: OMX: IBT.B wb_incandescent

Stock: XSTU: 9IB wb_incandescent

Details

Headquarters:

Bryggargatan 10

Stockholm, 111 21

Sweden

Phone: 46 7 06 70 12 26